Product News from the 02/03 News Brief
The FDA has approved Sucampo Pharmaceuticals’ Amitiza (lubiprostone) capsules, an oral treatment of chronic idiopathic constipation in adults. Amitiza is the first selective chloride channel activator approved for therapeutic use and has been found effective in the relief of chronic idiopathic constipation in adults.
CV Therapeutics’ Ranexa (ranolazine extended-release tablets) won FDA approval for the treatment of chronic angina.
The FDA has approved Cangene’s HepaGam B (hepatitis B immune globulin, human) for treatment following acute exposure to the hepatitis B virus.
The FDA granted ISTA Pharmaceuticals’ Xibrom (bromfenac ophthalmic solution) the expanded indication of treatment of pain following cataract surgery.